DOCSLIB.ORG

Microbial Transglutaminase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microbial Transglutaminase Transglutaminase ® Specialty reagents Titelseite Titel und Rückseite in separater Datei geliefert 2020 • Transglutaminases • Antibodies & Microarrays • Microbial Transglutaminase • Proteases 2020 • Protein Labeling • Cereal Proteins • Assays & Substrates • Blood Coagulation • Inhibitors • Celiac Disease Products Editorial Transglutaminases in Translation Driven by clinical programs, the transglutaminase researcher Our highly purified MTG is the product of choice for this purpose community enters an exciting and promising year. Sponsored and we expect to meet the increasing requirements of our by Dr. Falk Pharma, our tissue transglutaminase (TG2)-blocker customers for this enzyme, both in quantity and in conformity with ZED1227* entered a phase 2a proof-of-concept study for the stringent regulatory requirements. treatment of celiac disease in mid-2018. The study aims to enroll Autoantibodies to TG2 (celiac disease) and TG3 (dermatitis 160 patients in 20 centers all over Europe. The results of the herpetiformis) are well established biomarkers. In this context, “Study on the efficacy and tolerability of a 6-week treatment with Zedira continues to produce high quality diagnostic antigens. ZED1227 capsules vs. placebo in subjects with well-controlled Moreover, our patent protected anti-TG6-ab-ELISAs permit the celiac disease undergoing gluten challenge” detection of autoantibodies to TG6, a novel are going to be available in 2020. biomarker in gluten ataxia. The autoantibody test is now available for routine diagnostics Targeting TG2 for the treatment of fibrotic in the UK and the ELISA is soon going to be disorders has been discussed for several implemented in dedicated laboratories all years. In this regard, an anti-human over Europe. tissue transglutaminase monoclonal antibody (UCB7858, “Zampilimab”) is Factor XIII activity measurement is a under development. In late 2018, UCB diagnostic tool not only in FXIII-deficiency, Biopharma got approval for a phase but also for coagulation in routine blood 1/2 study “to evaluate safety/tolerability, tests. Our precise fluorogenic FXIII-activity pharmacokinetics, and efficacy of UCB7858 assay (A101, F001) is currently adapted to a in adult kidney transplant recipients with fully automated coagulation analyzer. Market chronic allograft injury” in Spain. launch is expected to be in early 2020. We are confident that the transglutaminase community will benefit These and many more aspects of “Transglutaminases in Translation” from the outcome of such clinical trials. We anticipate that obtaining will be highlighted in a special issue of Analytical Biochemistry, substantial data by means of target validation will increase the to be published in early 2020: “Transglutaminases in Translation overall awareness of the importance of the transglutaminase field – Novel Tools and Methods Impacting on Diagnostics and to pharmaceutical companies and to government funding agencies Therapeutics”. The special issue is meant to provide not only insight - resulting in more projects and increased financial support. into the latest basic research, but to figure out that the scientific results are already in translation for diagnostic, therapeutic, and We would like to mention Zedira’s own research that refocuses even technical purposes. on TG2. We are proud to announce that our scientists discovered We are honored to be guest editors for this special issue. Let us a novel class of potent and selective tissue transglutaminase already express our heartfelt gratitude to the numerous authors blockers, characterized by a reversible mode-of-inhibition. This for the so far submitted remarkable number of 20 exciting 2nd generation of TG2 inhibitors* was optimized for systemic publications, as well as to all the peer reviewers for their valuable indications, providing complementary small molecules to the support. monoclonal antibody approach. The overall aim is to improve the standard of care in e.g. lung, kidney, or liver fibrosis. Finally, we are proud to have been awarded ISO 9001:2015 certification. The internationally recognized standard ensures A current trend in oncology and, indeed in some other areas of Zedira’s products and services meet the needs of customers clinical research, is the development of antibody drug conjugates through an effective quality management system. (ADCs). Such innovative biomolecules enable the targeted delivery of cytotoxic payloads to cancer cells. Enzymatic conjugation by Sincerely yours, microbial transglutaminase (MTG) is a state-of-the-art method to produce site specifically conjugated and homogeneous ADCs with On behalf of the entire Zedira team a defined drug-to-antibody ratio. Ralf Pasternack and Martin Hils 2 Zedira is now certified according to DIN EN ISO 9001:2015 Content * Transglutaminases 4 Transglutaminases Microbial Transglutaminase 14 Protein Labeling 18 Assays & Substrates 22 Microbial Transglutaminase Inhibitors 32 Antibodies & Microarrays 39 Proteases 50 Protein Zedi - Zedira's transglutaminase mascot Labeling Cereal Proteins 51 In honor of Heinrich Waelsch, Nirmal Sarkar and Donald Clarke Blood Coagulation 52 who discovered transglutaminase in extracts from guinea pig liver in 1957, we chose the guinea pig Celiac Disease Products 58 as mascot. Zedi's mission is to inform you of novel Substates Services & Partnering 62 Assays and products and activities in the transglutaminase research field. Product List (alphanumeric) 64 In the catalogue Zedi highlights most important products we Order Sheet 71 recommend scientists working with transglutaminase. Inhibitors Stay informed on Zedira's new products as well as general Note / Contact activities like conferences in the fields of transglutaminase, celiac disease and thrombosis and haemostasis: The content of this catalogue is subject to change without notice. • Visit our homepage www.zedira.com Prices apply according to our website. To view latest product • Register for the Transglutaminase Newsletter developments, prices and availability please visit our homepage: Microarrays Antibodies and (send an e-mail to [email protected]) www.zedira.com. For any question please contact us via e-mail: [email protected]. Proteases Cover picture: Prinz-Georg-Garten (Darmstadt) The Prinz-Georg-Garten, located in the heart of Darmstadt, is a typical Rococo style garden, set out after French example and follows geometric formal design principles with its lawns, borders, Cereal Proteins Cereal fountains and sundials. It was a present of count Ludwig VIII to his son Prince Georg Wilhelm in 1764. The garden accommodates two important buildings. The Prinz- Blood Georg Palais, also called “Porzellanschlösschen” (porcelain Coagulation castle), is a baroque garden house, built in 1710. It contains the Grand Ducal Hessian porcelain collection. The Prettlack’sche Garden House (shown in the picture) was built in 1711 from lieutenant-general Johann Rudolf von Prettlack. It is elaborately painted with trees, vines and garlands. Products Celiac Disease Celiac visit www.zedira.com for more detailed information 3 Transglutaminases Transglutaminases Background information The history of the enzyme class of transglutaminases started one basic common feature – the formation of high molecular more than 60 years ago, when the term transglutaminase (TG) weight aggregates by covalent protein cross-linking – they fulfill a was introduced in scientific literature by Heinrich Waelsch and multitude of other catalytic and physiological functions. co-workers. The sketch below gives you a rough overview about the members Today, we know that we are talking about a family of nine different and their implications in physiology, diseases and diagnostics - as isoenzymes in the human body. Although transglutaminases have it is known today. Deficiencies Diagnostic markers Functions TG1: lammellar ichthyosis TG2-autoantibodies cross-linking TG3: uncombable hair syndrome TG3-autoantibodies protein modification TG5: acral peeling skin syndrome TG6-autoantibodies signaling (G-protein) FXIII: bleeding, impaired wound Factor XIII-activity structural protein healing, abortions Location Autoimmune diseases intracellular, extracellular celiac disease intranuclear dermatitis herpetiformis plasma gluten ataxia Cell biology Neurodegeneration differentiation Alzheimer‘s disease cell adhesion Chorea huntington apoptosis Parkinson‘s disease cell-cell interaction cell-matrix interaction Eyes phagocytosis cataract formation vascularisation wound healing Skin diseases inflammation akne, psoriasis receptor mediated endocytosis Fibrosis Skin scarring cornified envelope formation scleroderma trans-epidermal water loss lung fibrosis barrier function liver fibrosis and cirrhosis The transglutaminase family diabetic nephropathy TG1: keratinocyte transglutaminase Coagulation TG2: tissue transglutaminase fibrin cross-linking Cancer TG3: epidermal transglutaminase decoration with antifibrinolytics drug resistance TG4: prostate translgutaminase clot stability carcinogenesis TG5: transglutaminase 5 half-life and composition vascularisation TG6: neuronal transglutaminase TG7: transglutaminase 7 ECM FXIII: blood coagulation factor XIII stabilisation B4.2: inactive structural protein attachment and spreading of cells profibrotic factor 4 Products Transglutaminase 1 Transglutaminases Synonyms: Keratinocyte transglutaminase, TG1, TGase 1, TGK Art. No. Name Unit Price T009 Human keratinocyte transglutaminase 150 µg 370 € (TG1, recombinantly produced in E. coli) Reference: Chrobok et al., PLoS One.
Load more

Recommended publications
  • Plant Protease Inhibitors: a Defense Strategy in Plants
    Biotechnology and Molecular Biology Review Vol. 2 (3), pp. 068-085, August 2007 Available online at http://www.academicjournals.org/BMBR ISSN 1538-2273 © 2007 Academic Journals Standard Review Plant protease inhibitors: a defense strategy in plants Huma Habib and Khalid Majid Fazili* Department of Biotechnology, The University of Kashmir, P/O Naseembagh, Hazratbal, Srinagar -190006, Jammu and Kashmir, India. Accepted 7 July, 2007 Proteases, though essentially indispensable to the maintenance and survival of their host organisms, can be potentially damaging when overexpressed or present in higher concentrations, and their activities need to be correctly regulated. An important means of regulation involves modulation of their activities through interaction with substances, mostly proteins, called protease inhibitors. Some insects and many of the phytopathogenic microorganisms secrete extracellular enzymes and, in particular, enzymes causing proteolytic digestion of proteins, which play important roles in pathogenesis. Plants, however, have also developed mechanisms to fight these pathogenic organisms. One important line of defense that plants have to fight these pathogens is through various inhibitors that act against these proteolytic enzymes. These inhibitors are thus active in endogenous as well as exogenous defense systems. Protease inhibitors active against different mechanistic classes of proteases have been classified into different families on the basis of significant sequence similarities and structural relationships. Specific protease inhibitors are currently being overexpressed in certain transgenic plants to protect them against invaders. The current knowledge about plant protease inhibitors, their structure and their role in plant defense is briefly reviewed. Key words: Proteases, enzymes, protease inhibitors, serpins, cystatins, pathogens, defense. Table of content 1.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • (A) Enzymes Derived from Animal Sources
    ANNEX (new entries are highlighted in yellow) PERMITTED ENZYMES (A) Enzymes derived from animal sources Enzyme EC Number Source Catalase 1.11.1.6 Bovine liver Lactoperoxidase 1.11.1.7 Bovine milk Bovine stomach; salivary glands or forestomach of calf, kid or lamb; porcine Lipase, triacylglycerol 3.1.1.3 or bovine pancreas Lysozyme 3.2.1.17 Egg whites Pancreatin (or pancreatic elastase) 3.4.21.36 Pancreas of the hog or ox Pepsin 3.4.23.1 Bovine or porcine stomach Phospholipase A2 3.1.1.4 Porcine pancreas Aqueous extracts from the fourth stomach of calves, kids, lambs, and adult Rennet 3.4.23.4 bovine animals, sheep and goats Thrombin 3.4.21.5 Bovine or porcine blood Trypsin 3.4.21.4 Porcine or bovine pancreas (B) Enzymes derived from plant sources Enzyme EC Number Source Alpha–amylase 3.2.1.1 Malted cereals Actinidin 3.4.22.14 Kiwifruit (Actinidia deliciosa) Malted cereals Beta-Amylase 3.2.1.2 Sweet potato (Ipomoea batatas) Bromelain 3.4.22.4 Pineapple fruit/stem (Ananas comosus and Ananas bracteatus (L)) Ficin 3.4.22.3 Ficus spp. Lipoxidase 1.13.11.12 Soyabean whey or meal Papain 3.4.22.2 Carica papaya (L) (Fam. Caricaceae) (C) Enzymes derived from microbial sources EC Enzyme Production organism Donor organism Donor gene Number 1,4-alpha-glucan branching 1,4-alpha-glucan branching 2.4.1.18 Bacillus subtilis Rhodothermus obamensis enzyme enzyme Alpha-acetolactate decarboxylase 4.1.1.5 Bacillus amyloliquefaciens Bacillus subtilis Bacillus subtilis Bacillus brevis Alpha-acetolactate decarboxylase Alpha-amylase 3.2.1.1 Aspergillus niger1 Aspergillus
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 28 April 2020 REGISTER of FOOD
    EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Food and feed safety, innovation Food processing technologies and novel foods Brussels, 28 April 2020 REGISTER OF FOOD ENZYMES TO BE CONSIDERED FOR INCLUSION IN THE UNION LIST Article 17 of Regulation (EC) No 1332/20081 provides for the establishment of a Register of all food enzymes to be considered for inclusion in the Union list. In accordance with that Article, the Register includes all applications which were submitted within the initial period fixed by that Regulation and which comply with the validity criteria laid down in accordance with Article 9(1) of (EC) No 1331/2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings2. The Register therefore lists all valid food enzyme applications submitted until 11 March 2015 except those withdrawn by the applicant before that date. Applications submitted after that date are not included in the Register but will be processed in accordance with the Common Authorisation Procedure. The entry of a food enzyme in the Register specifies the identification, the name, the source of the food enzyme as provided by the applicant and the EFSA question number under which the status of the Authority’s assessment can be followed3. As defined by Article 3 of Regulation (EC) No 1332/2008, ‘food enzyme’ subject to an entry in the Register, refers to a product that may contain more than one enzyme capable of catalysing a specific biochemical reaction. In the assessment process, such a food enzyme may be linked with several EFSA question numbers.
    [Show full text]
  • Biochemical Aspects of Seeds from Cannabis Sativa L. Plants Grown In
    www.nature.com/scientificreports OPEN Biochemical aspects of seeds from Cannabis sativa L. plants grown in a mountain environment Chiara Cattaneo1*, Annalisa Givonetti1, Valeria Leoni2,3, Nicoletta Guerrieri4, Marcello Manfredi5, Annamaria Giorgi2,3 & Maria Cavaletto1 Cannabis sativa L. (hemp) is a versatile plant which can adapt to various environmental conditions. Hempseeds provide high quality lipids, mainly represented by polyunsaturated acids, and highly digestible proteins rich of essential aminoacids. Hempseed composition can vary according to plant genotype, but other factors such as agronomic and climatic conditions can afect the presence of nutraceutic compounds. In this research, seeds from two cultivars of C. sativa (Futura 75 and Finola) grown in a mountain environment of the Italian Alps were analyzed. The main purpose of this study was to investigate changes in the protein profle of seeds obtained from such environments, using two methods (sequential and total proteins) for protein extraction and two analytical approaches SDS-PAGE and 2D-gel electrophoresis, followed by protein identifcation by mass spectrometry. The fatty acids profle and carotenoids content were also analysed. Mountain environments mainly afected fatty acid and protein profles of Finola seeds. These changes were not predictable by the sole comparison of certifed seeds from Futura 75 and Finola cultivars. The fatty acid profle confrmed a high PUFA content in both cultivars from mountain area, while protein analysis revealed a decrease in the protein content of Finola seeds from the experimental felds. Cannabis sativa L. (hemp) is an annual plant belonging to the family of Cannabaceae. C. sativa is naturally dioe- cious, however this plant has been domesticated by humans since the prehistoric era and monoecious varieties have been selected to obtain higher quality fbers and to optimize seed harvest procedures1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • Comparative Analysis of Secretome Profiles of Manganese(II)- Oxidizing Ascomycete Fungi
    Comparative Analysis of Secretome Profiles of Manganese(II)- Oxidizing Ascomycete Fungi The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Zeiner, C. A., S. O. Purvine, E. M. Zink, L. Paša-Tolić, D. L. Chaput, S. Haridas, S. Wu, et al. 2016. “Comparative Analysis of Secretome Profiles of Manganese(II)-Oxidizing Ascomycete Fungi.” PLoS ONE 11 (7): e0157844. doi:10.1371/journal.pone.0157844. http:// dx.doi.org/10.1371/journal.pone.0157844. Published Version doi:10.1371/journal.pone.0157844 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002694 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA RESEARCH ARTICLE Comparative Analysis of Secretome Profiles of Manganese(II)-Oxidizing Ascomycete Fungi Carolyn A. Zeiner1¤a, Samuel O. Purvine2, Erika M. Zink3, Ljiljana Paša-Tolić2, Dominique L. Chaput4, Sajeet Haridas5,SiWu2¤b, Kurt LaButti5, Igor V. Grigoriev5, Bernard Henrissat6,7, Cara M. Santelli8, Colleen M. Hansel9* 1 School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States of America, 2 Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, a11111 Richland, Washington, United States of America, 3 Biological Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington, United States of America, 4 Department of Mineral Sciences, National Museum of Natural History, Smithsonian Institution, Washington, DC, United States of America, 5 U.S.
    [Show full text]
  • Hemp: a Composition Review Plus
    HEMP: A COMPOSITION REVIEW PLUS By Agustin Gonzalo Miguel Garcia (Fall quarter) A Senior Project submitted In partial fulfillment of the requirements for the degree of Bachelor of Science in Nutrition Food Science and Nutrition Department California Polytechnic State University San Luis Obispo, CA January 2017 Garcia, Agustin G.M.. Hemp: a composition review plus (2017). Senior project for B.S. Nutrition at Cal Poly San Luis Obispo. San Luis Obispo, CA. Hemp has been utilized by many societies around the world yet is currently absent in U.S. food production. The paper described and assessed various sources to aggregate hemp seed composition data and to decipher hemp seed consumption effect on health. There are copious components in hemp seeds that are discussed; some beneficial to human health as well as some antinutritional components that interfere. Numerous articles were analyzed and aspects of each were compiled to provide a source to assess the effectiveness of hemp seed as a nutritious source. Many components found in hemp seeds are found to be beneficial to human health and discussed in detail; from high amounts of polyunsaturated fatty acids (PUFA), to complete, digestible proteins, to present micronutrients and to the “contaminant” cannabinoids. Hemp contains many nutriments that could help nourish a healthy nation and combat this nation’s diet-related disease problem, plus the plant easy to grow and can be beneficial to the environment. This paper demonstrates the multi-purposefulness of hemp and how it can be utilized beyond production of hemp seeds. Hemp: A Composition Review Plus Introduction The effect of polyunsaturated fatty acids (PUFA) on health (especially when replacing saturated fatty acids [SAFA] for PUFA) has been extensively studied to suggest that they provide beneficial effects on health (Zock P.
    [Show full text]
  • Wo 2008/127646 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127646 A2 (51) International Patent Classification: Not classified AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (21) International Application Number: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, PCT/US2008/004699 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, (22) International Filing Date: 10 April 2008 (10.04.2008) MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, (25) Filing Language: English PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 60/922,994 11 April 2007 (11.04.2007) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): BIOVER- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), DANT, INC. [US/US] ; 7330 Carroll Road, San Diego, CA European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, 92121 (US). FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, (72) Inventors; and CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • 16. the Denaturation of Edestin by Acid: T
    16. The Denaturation of Edestin by Acid: T. B. Osborne's Edestan By Kenneth Bailey, From the Biochemical Department, Imperial Colege of Science and Technology, London, S. W. 7 (Received 29 January 1942) Certain denaturation products of the seed globulins, edestin and excelsin, have been studied by X-ray diffraction analysis [Astbury et al. 1935]. The fundamental observation emerging from this research was that a corpuscular protein could be denatured and mani- pulated to give a molecular pattern resembling that of#-keratin. We were tempted by this revelation to depart from the classical definition of protein denaturation, and to designate the /3-keratin structure, or some approximation to it, as representing the final state of denaturation processes. At the same time, it was apparent that intermediate stages of protein degradation could be distinguished. Diffraction photographs of large air-dried excelsin crystals indicated a partial transition from the crystalline globular arrangement of the protein molecules to a more fibrousstate. It seemed desirable at this stage to investigate in some detail the conditions governing the formation of these intermediate denaturation products, derived on the one hand from a molecule of precise and perhaps unique configuration, and giving rise by suitable treatment to a well-defined fibrous configuration. At the beginning of the century, T. B. Osborne [1901; 1902, 1, 2] became interested in the formatlon of protein derivatives which he called protean8, and he gave particular attention to edestan, the protean derivative of hemp-seed globulin. The proteans were defined as the salt-insoluble globulin derivatives produced in small amounts during crystallization and preparative processes, and especially by the action of the most dilute acids.
    [Show full text]